Clinical Trials Logo

Filter by:
NCT ID: NCT04813055 Recruiting - Clinical trials for Chronic Pancreatitis

Prospective Registry Of Therapeutic EndoscopiC ulTrasound

PROTECT
Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

This registry aims to analyze long-term outcomes of therapeutic EUS (T-EUS) procedures, as well as to describe clinical and technical variables potentially predicting clinical success or adverse events, for a better selection of ideal candidates.

NCT ID: NCT04813029 Recruiting - Clinical trials for Gastroesophageal Reflux

Thresholds of Straight Leg Raise Maneuver During High-Resolution-Manometry

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

High resolution manometry (HRM) is a key test in the preoperative assessment of patients with gastro-esophageal reflux disease (GERD) who are potential candidates for antireflux surgery. The recent Lyon consensus suggested the potential usefulness of HRM in diagnosing GERD, however, sensitivity and specificity of HRM for GERD remains low (53.6% and 72.5% respectively). Among recently proposed provocative tests during manometry, a traditional maneuver (straight leg raise maneuver, SLR) appeared promising in predicting reflux. This is a multicenter study involving high-volume esophageal function laboratories around the world. Patients with suspected GERD and tested with HRM and pH-impedance will be asked to perform SLR during HRM. Intra-abdominal and intra-esophageal pressure during SLR will be recorded and compared with acid exposure time (AET) at pH-impedance. Primary aim is to determine the optimal threshold of intra-esophageal pressure augmentation during straight leg raise (SLR) maneuver that predicts pathological esophageal acid exposure time (AET). Secondary aim is to assess the diagnostic performance of HMR with SRL maneuver, calculating sensitivity, specificity, false-positive rate (FPR), false-negative rate (FNR), positive predictive value and total misclassification rate.

NCT ID: NCT04812951 Completed - Clinical trials for Ocular Surface Disease

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery

CSA2020
Start date: February 17, 2021
Phase: Early Phase 1
Study type: Interventional

Use of Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in cataract Surgery

NCT ID: NCT04812938 Not yet recruiting - Ovarian Cancer Clinical Trials

Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

PAPAudit
Start date: April 12, 2021
Phase:
Study type: Observational

The aim of the project is to corroborate them on a large retrospective cohort of HGS-EOC and confirm the possibility of identify TP53 mutations in high grade endometrioid tumors. This will consequently allow to confirm the previous results and define with a greater precision the temporal windows in which it will be possible to detect, through the TP53 analysis, tumor material by vaginal swab sampling. The results of the study will be the first step of a multiphase prospective validation program for the development of a novel approach for early diagnosis of EOC.

NCT ID: NCT04812925 Active, not recruiting - Clinical trials for Primary Immune Thrombocytopenia

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

ADVANCE SC+
Start date: November 17, 2021
Phase: Phase 3
Study type: Interventional

A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia

NCT ID: NCT04812782 Completed - Type 1 Diabetes Clinical Trials

Dietary Fat and Endothelial Function in Type 1 Diabetes

Start date: February 12, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effects of the add-on of extra vergin olive oil or butter to a high glycemic index meal on endothelial function in subjects with type 1 Diabetes and healthy subjects.

NCT ID: NCT04812548 Terminated - Clinical trials for Myelodysplastic Syndrome (MDS)

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

STIMULUS-MDS3
Start date: May 31, 2021
Phase: Phase 2
Study type: Interventional

The purpose of the study was to find out if the new drug sabatolimab when given in combination with azacitidine and venetoclax, was safe and had beneficial effects in participants with high or very high risk myelodysplastic syndrome (MDS) who were not suitable for treatment with intensive chemotherapy or a stem-cell transplant (HSCT).

NCT ID: NCT04811898 Completed - Clinical trials for Advanced Solid Tumor

A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment

LNA-i-miR221
Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

The LNA-i-miR-221 Phase I trial has been designed as a monocentric open label dose escalation study which received written approval by the Competent Authority and independent Ethics Committee (IEC). LNA-i-miR-221 will be investigated for safety and tolerability in patients, men and women age ≥18 yrs, affected by Refractory-MM and advanced solid tumors.

NCT ID: NCT04811781 Completed - Solid Tumor, Adult Clinical Trials

Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study

Start date: June 4, 2020
Phase:
Study type: Observational

The study aims to retrospectively collect epidemiological and clinical data in patients with solid tumors and SARS Covid2 infections belonging to oncology centers within the Veneto Oncology Network

NCT ID: NCT04811365 Completed - Clinical trials for Systemic Mast Cell Activation

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

Start date: June 29, 2021
Phase:
Study type: Observational

This is a multi-center screening study with the primary objective to determine the prevalence of KIT D816V mutation in peripheral blood in patients with evidence of systemic mast cell activation (MCA).